Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Exclusion Criteria

• •History of hypersensitivity reactions to glucagon or dasiglucagon or any of the excipients
• •History of insulinoma, pheochromocytoma, MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease.
• •Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m2 or end-stage renal disease at screening
• •Hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase ≥ 2.5 times the upper limit of normal (ULN)
• •Active malignancy, except for basal or squamous cell skin cancers
• •History of a cerebrovascular accident within 6 months prior to screening
• •History of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening.
• •Congestive heart failure, New York Heart Association Class III or IV
• •Concurrent administration of β-blocker therapy
• •Clinically significant ECG abnormalities at screening